Assignee
NANTBIO INC
US·43 granted patents·36 pending applications·44 citations·filing 2016–2025
Top patents by PatentIndex Score
79 records- 0193US10724043B2Multi-pulse transfection methods and cellsNANTBIO INC·Filed 2017·Granted Jul 28, 2020·21 cites·17 claims
- 0292US11753467B2Anti-TIM3 monoclonal antibodies and chimeric antigen receptorsNANTBIO INC·Filed 2022·Granted Sep 12, 2023·2 cites·20 claims
- 0392US11298414B2Cellular adjuvants for viral infectionNANTBIO INC·Filed 2019·Granted Apr 12, 2022·6 cites·8 claims
- 0491US10814011B1Anti-B7-H4 antibodies and methodsNANTBIO INC·Filed 2018·Granted Oct 27, 2020·7 cites·26 claims
- 0589US12350323B2Cellular adjuvants for viral infectionNANTBIO INC·Filed 2024·Granted Jul 8, 2025·0 cites·18 claims
- 0688US12329809B2Cellular adjuvants for viral infectionNANTBIO INC·Filed 2024·Granted Jun 17, 2025·0 cites·18 claims
- 0788US2025369959A1Live Cell Imaging Systems & Methods of UseNANTBIO INC·Filed 2025·Application pending·0 cites
- 0886US11034951B2mRNA display antibody library and methodsNANTBIO INC·Filed 2019·Granted Jun 15, 2021·2 cites·7 claims
- 0984US12263189B2Mesenchymal stem cell derived exosomes and methodsNANTBIO INC·Filed 2019·Granted Apr 1, 2025·1 cites·7 claims
- 1084US10752682B2Anti-IL8 antibodiesNANTBIO INC·Filed 2018·Granted Aug 25, 2020·2 cites·10 claims
- 1183US11015188B2MRNA display antibody library and methodsNANTBIO INC·Filed 2018·Granted May 25, 2021·2 cites·13 claims
- 1282US12416635B2Live cell imaging systems and methods to validate triggering of immune responseNANTBIO INC·Filed 2022·Granted Sep 16, 2025·0 cites·13 claims
- 1382US2024263355A1mRNA display antibody library and methodsNANTBIO INC·Filed 2024·Application pending·0 cites
- 1481US12397019B2Mesenchymal stem cell derived exosomes and methodsNANTBIO INC·Filed 2024·Granted Aug 26, 2025·0 cites·8 claims
- 1581US2025262288A1Cellular Adjuvants for Viral InfectionNANTBIO INC·Filed 2025·Application pending·0 cites
- 1679US12220452B2Cellular adjuvants for viral infectionNANTBIO INC·Filed 2022·Granted Feb 11, 2025·0 cites·19 claims
- 1779US12098201B2Anti-TIM3 monoclonal antibodies and chimeric antigen receptorsNANTBIO INC·Filed 2023·Granted Sep 24, 2024·0 cites·19 claims
- 1879US2024209384A1Multi-Pulse Transfection Methods And CellsNANTBIO INC·Filed 2024·Application pending·0 cites
- 1979US2023230654A1Validation of inferred anticancer pathwaysNANTBIO INC·Filed 2023·Application pending·0 cites
- 2079US2024336684A1Anti-TIM3 monoclonal antibodies and chimeric antigen receptorsNANTBIO INC·Filed 2024·Application pending·0 cites
- 2178US12247086B2Enhanced immunogenicity for GPI-anchored antigensNANTBIO INC·Filed 2023·Granted Mar 11, 2025·0 cites·18 claims
- 2277US2024294875A1Reprogrammed T Cell-Like NK CellsNANTBIO INC·Filed 2024·Application pending·0 cites
- 2377US2024350603A1Method Of Validating The Triggering Of An Immune Response To A Neoepitope Of A Tumor With T-CellsNANTBIO INC·Filed 2024·Application pending·0 cites
- 2477US2024190945A1mRNA display antibody library and methodsNANTBIO INC·Filed 2023·Application pending·0 cites
- 2576US2023406918A1Method of treatment of a tumor with il-8 antibodyNANTBIO INC·Filed 2023·Application pending·0 cites
- 2674US2024360191A1Targeted IL-12 Treatments and Methods to Stimulate haNK and NK92mi CellsNANTBIO INC·Filed 2024·Application pending·0 cites
- 2774US2024272141A1Interferometry Based Systems To Detect Small Mass Changes Of An Object In a SolutionNANTBIO INC·Filed 2024·Application pending·0 cites
- 2873US12060655B2mRNA display antibody library and methodsNANTBIO INC·Filed 2021·Granted Aug 13, 2024·0 cites·7 claims
- 2973US2023270879A1Anti-B7-H4 Antibodies And MethodsNANTBIO INC·Filed 2023·Application pending·0 cites
- 3071US11912756B2MRNA display antibody library and methodsNANTBIO INC·Filed 2021·Granted Feb 27, 2024·0 cites·5 claims
- 3171US10344026B2Compositions and methods of targeting mutant K-rasNANTBIO INC·Filed 2018·Granted Jul 9, 2019·1 cites·15 claims
- 3270US12350316B2IL7-IL 15 TxM compositions and methodsNANTBIO INC·Filed 2019·Granted Jul 8, 2025·0 cites·7 claims
- 3370US2025276040A1IL7-IL15 TxM Compositions and MethodsNANTBIO INC·Filed 2025·Application pending·0 cites
- 3469US11939585B2Multi-pulse transfection methods and cellsNANTBIO INC·Filed 2020·Granted Mar 26, 2024·0 cites·16 claims
- 3568US12280092B2Reprogrammed T cell-like NK cellsNANTBIO INC·Filed 2019·Granted Apr 22, 2025·0 cites·5 claims
- 3668US11773158B2Method of treatment of a tumor with an IL-8 antibodyNANTBIO INC·Filed 2020·Granted Oct 3, 2023·0 cites·12 claims
- 3768US11773187B2Enhanced immunogenicity for GPI-anchored antigensNANTBIO INC·Filed 2019·Granted Oct 3, 2023·0 cites·6 claims
- 3868US11672873B1Anti-B7-H4 antibodies and methodsNANTBIO INC·Filed 2020·Granted Jun 13, 2023·0 cites·20 claims
- 3968US10736884B2Compositions and methods of Rit1 inhibitionNANTBIO INC·Filed 2019·Granted Aug 11, 2020·0 cites·1 claims
- 4068US2024358760A1Primary T-Cell ExpansionNANTBIO INC·Filed 2024·Application pending·0 cites
- 4168US2023039169A1Modified EC7 Cells Having Low Toxicity to Viral Production PayloadsNANTBIO INC·Filed 2022·Application pending·0 cites
- 4266US2024124598A1Anti-CD30 monoclonal antibodies and chimeric antigen receptorsNANTBIO INC·Filed 2023·Application pending·0 cites
- 4365US11814436B2Anti-CD30 monoclonal antibodies and chimeric antigen receptorsNANTBIO INC·Filed 2022·Granted Nov 14, 2023·0 cites·18 claims
- 4465US2025179217A1Enhanced Immunogenicity For GPI-anchored AntigensNANTBIO INC·Filed 2025·Application pending·0 cites
- 4564US12098177B2Targeted IL-12 treatments and methods to stimulate haNK and NK92mi cellsNANTBIO INC·Filed 2019·Granted Sep 24, 2024·0 cites·17 claims
- 4664US12019067B2Interferometry based systems to detect small mass changes of an object in a solutionNANTBIO INC·Filed 2021·Granted Jun 25, 2024·0 cites·11 claims
- 4763US2024352533A1Monocarboxylic Acid Transporter 4 as a Biomarker for Hypoxia Driven Tumor Growth and TreatmentNANTBIO INC·Filed 2024·Application pending·0 cites
- 4862US12252525B2Chimeric T cell receptors, nucleic acids, and methods of making and using the sameNANTBIO INC·Filed 2021·Granted Mar 18, 2025·0 cites·27 claims
- 4962US12053512B2Method of validating the triggering of an immune response to a neoepitope of a tumor with t-cellsNANTBIO INC·Filed 2017·Granted Aug 6, 2024·0 cites·11 claims
- 5062US10668076B1Compositions and methods of targeting mutant K-RasNANTBIO INC·Filed 2017·Granted Jun 2, 2020·0 cites·8 claims
Showing the top 50 of 79 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when NANTBIO INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →